CANbridge Pharmaceuticals Inc. (HK:1228) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CANbridge Pharmaceuticals Inc. has announced that their drug CAN103, aimed at treating Gaucher Disease, has been awarded priority review status in China, signaling a significant step towards meeting the high demand for treatment among Chinese patients. The priority review status is a result of the company’s promising clinical trial outcomes and could lead to the drug being the first enzyme replacement therapy for Gaucher Disease developed and produced domestically in China. CANbridge specializes in creating transformative therapies for rare diseases, with a portfolio that includes three approved drugs and nine assets in development.
For further insights into HK:1228 stock, check out TipRanks’ Stock Analysis page.